Embecta restructures again, outlines tariff costs
The diabetes tech company announced a second restructuring after ending its insulin patch-pump program.
| Ticker |
EMBC
|
| CIK | 0001872789 |
| SIC | 3841 |
| Sector | Manufacturing |
| Industry Category | Medical Equipment |
| Industry Group | Surgical, Medical, And Dental Instruments And Supplies |
| Address | 1209 ORANGE STREET, WILMINGTON, DE, 19801 |
| Website | embecta.com |
| Phone | 8624010000 |
| CEO | Devdatt Kurdikar |
| Employees | 1,900 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Embecta restructures again, outlines tariff costsThe diabetes tech company announced a second restructuring after ending its insulin patch-pump program. Embecta Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagEmbecta ( NASDAQ:EMBC ) Second Quarter 2025 Results Key Financial Results Revenue: US$259.0m (down 9.8% from 2Q 2024... Embecta Corp (EMBC) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue DeclineEmbecta Corp (EMBC) navigates challenges with strategic initiatives and financial resilience despite a year-over-year revenue dip. Why Is Embecta Stock Falling On Friday?Embecta Corp. (NASDAQ:EMBC) posted on Friday the second-quarter 2025 adjusted earnings of 70 cents per share, up from 67 cents a year ago, beating the consensus of 53 cents. The diabetes care company reported sales of $259 million, beating the consensus of $253.94 million. Revenues were down 9.8% on a reported basis, down 7.7% on an adjusted constant currency basis. U.S. revenues decreased 8.4% on both a reported and adjusted constant currency basis. International revenues decreased 11.3% on a r |